^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    risvutatug rezetecan (GSK5764227)

    i
    Other names: GSK5764227, HS-20093, HS20093, HS 20093, GSK 5764227, GSK-5764227, GSK’227
    Associations

    News

    Trials
    Company:
    GSK, Jiangsu Hansoh Pharma
    Drug class:
    Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    1d
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)
    7d
    Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=63, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-5041 • risvutatug rezetecan (GSK5764227)
    26d
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • risvutatug rezetecan (GSK5764227)
    1m
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=158, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2028 --> Aug 2027 | Trial primary completion date: Sep 2028 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608) • risvutatug rezetecan (GSK5764227)
    3ms
    Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    itraconazole • risvutatug rezetecan (GSK5764227)
    4ms
    A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P3, N=300, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open
    |
    topotecan • risvutatug rezetecan (GSK5764227)
    4ms
    Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=63, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    HRS-5041 • risvutatug rezetecan (GSK5764227)
    4ms
    A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (clinicaltrials.gov)
    P1/2, N=320, Recruiting, GlaxoSmithKline | N=200 --> 320 | Trial completion date: Feb 2028 --> Jun 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    risvutatug rezetecan (GSK5764227)
    4ms
    A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, GlaxoSmithKline
    New P3 trial
    |
    topotecan • risvutatug rezetecan (GSK5764227)
    5ms
    Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Shanghai Hansoh Biomedical Co., Ltd
    New P1 trial
    |
    AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    6ms
    A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (clinicaltrials.gov)
    P1/2, N=200, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | N=120 --> 200
    Enrollment open • Enrollment change
    |
    risvutatug rezetecan (GSK5764227)
    6ms
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=157, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • docetaxel • AiTan (rivoceranib) • albumin-bound paclitaxel • irinotecan • GSK5733584 • HS-10502 • risvutatug rezetecan (GSK5764227)